| Code | CSB-RA004845MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in patent WO2022126180, specifically targeting CCR6 (C-C chemokine receptor type 6). CCR6 is a G protein-coupled receptor that binds the chemokine CCL20 and plays a critical role in the migration and positioning of immune cells, particularly Th17 cells, regulatory T cells, and B cells. This receptor is expressed on various lymphocyte subsets and is essential for their trafficking to inflammatory sites and mucosal tissues. CCR6 has been implicated in numerous autoimmune and inflammatory conditions, including psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as well as in certain cancers where it influences tumor immunity and metastasis.
The reference antibody documented in WO2022126180 represents a well-characterized tool for investigating CCR6-mediated pathways. This biosimilar antibody serves as a valuable research reagent for studying CCR6 expression patterns, immune cell migration mechanisms, and the receptor's involvement in disease pathogenesis. It enables researchers to explore therapeutic targeting strategies and elucidate the role of the CCR6-CCL20 axis in various immunological contexts.
There are currently no reviews for this product.